1st Edition

Statistical Methods in Drug Combination Studies

Edited By Wei Zhao, Harry Yang Copyright 2015
240 Pages
by Chapman & Hall

240 Pages 52 B/W Illustrations
by Chapman & Hall

240 Pages
by Chapman & Hall

The growing interest in using combination drugs to treat various complex diseases has spawned the development of many novel statistical methodologies. The theoretical development, coupled with advances in statistical computing, makes it possible to apply these emerging statistical methods in in vitro and in vivo drug combination assessments. However, despite these advances, no book has served... Read more

Drug Combination: Much Promise and Many Hurdles. Drug Combination Synergy. Drug Combination Design Strategies. Confidence Interval for Interaction Index. Two-Stage Response Surface Approaches to Modeling Drug Interaction. A Bayesian Industry Approach to Phase I Combination Trials in Oncology. Statistical Methodology for Evaluating Combination Therapy in Clinical Trials. Challenges and Opportunities in Analysis of Drug Combination Clinical Trial Data. Software and Tools to Analyze Drug Combination Data.

Biography

Wei Zhao, Harry Yang

"This book is a welcome addition to the literature and fills a needed niche since last book written on drug synergism was over 15 years ago . . .  each chapter presents a different technique for solving common challenges in the development of drug combinations. . . Overall, this book serves as a good reference for both researchers in the field of statistics and drug combination development."
~ Jessica L. Jaynes, California State University, Fullerton

"Investigating drug combinations is a steadily growing area in preclinical and clinical research.As usual, specific statistical methodology is needed to handle these kinds of trials. . . .the book is generallywell structured and the majority of sections actually builds up on and refers to each other. This book provides a good overview on and a good introduction to the topic of statistical methods for drug combination studies, especially regarding the preclinical part."
~ Tim Holland-Letz, German Cancer Research Center Heidelberg